Alpelisib
87 interactions 52 cited referencesAlpelisib (Piqray) is used in combination with fulvestrant (Faslodex) to treat a certain type of breast cancer that has spread to nearby tissues or other parts of the body in women who have already gone through menopause (''change of life,'' end of menstrual periods) or in men, whose cancer got worse during or after ce… Read the full Alpelisib drug information page →
Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →
Moderate
Alpelisib Artemether Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Alpelisib Kratom Increased CYP3A substrate exposure Details Alpelisib Mavacamten Camzyos Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Alpelisib Rilzabrutinib Wayrilz Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Alpelisib Zongertinib Hernexeos Increased BCRP substrates exposure and an increased risk of BCRP substrates-related adverse reactions DetailsNo interactions on this page match that filter — try the next page or clear the filter.
Check another drug
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist